Annotation Detail
Information
- Associated Genes
- IDH1
- Associated Variants
-
IDH1 MUTATION
IDH1 MUTATION - Associated Disease
- acute myeloid leukemia
- Source Database
- CIViC Evidence
- Description
- I phase 1 trial for patients with IDH1-mutated AML, patients who received ivosidenib (AG-120). The rate of complete remission was 21.6%, the over all response rate was 30.4%.
- Variant Origin
- somatic
- Variant Origin
- Somatic
- Evidence URL
- https://civic.genome.wustl.edu/links/evidence_items/7278
- Gene URL
- https://civic.genome.wustl.edu/links/genes/26
- Variant URL
- https://civic.genome.wustl.edu/links/variants/645
- Rating
- 3
- Evidence Type
- Predictive
- Disease
- Acute Myeloid Leukemia
- Evidence Direction
- Supports
- Drug
- Ivosidenib
- Evidence Level
- A
- Clinical Significance
- Sensitivity/Response
- Pubmed
- 29860938
Drugs
| Drug Name | Sensitivity | Supported |
|---|---|---|
| Ivosidenib | Sensitivity | true |